FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Phase 1

Terminated

Conditions: Stage IV Non-Small Cell Lung Cancer AJCC v7
Stage IV Pleural Malignant Mesothelioma AJCC v7
WT1 Positive
Advanced Pleural Malignant Mesothelioma
HLA-A*0201 Positive Cells Present
Recurrent Non-Small Cell Lung Carcinoma
Stage III Pleural Malignant Mesothelioma AJCC v7
Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Recurrent Pleural Malignant Mesothelioma
Stage III Non-Small Cell Lung Cancer AJCC v7

Interventions: Biological: Aldesleukin
Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2015-04-03

Last Posted Date: 2021-09-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 11

Registration Number: NCT02408016

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

theFRESHstudy: FRequency of Eating and Its Influence on Satiety and Health

Not Applicable

Completed

Conditions: Healthy

Interventions: Behavioral: High Eating Frequency
Behavioral: Low Eating Frequency

First Posted Date: 2015-03-19

Last Posted Date: 2019-07-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT02392897

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Phase 1

Withdrawn

Conditions: HIV Infection
AIDS-Related Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
AIDS-Related Non-Hodgkin Lymphoma
Recurrent Non-Hodgkin Lymphoma

Interventions: Biological: Gene-Modified HIV-Protected Hematopoietic Stem Cells
Other: Laboratory Biomarker Analysis
Other: Transplant Conditioning

First Posted Date: 2015-03-04

Last Posted Date: 2018-12-27

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02378922

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Phase 1

Withdrawn

Conditions: Human Immunodeficiency Virus 1 Positive
Stage I Adult Hodgkin Lymphoma
Stage I Adult Non-Hodgkin Lymphoma
Stage II Adult Hodgkin Lymphoma
Stage II Adult Non-Hodgkin Lymphoma
Stage III Adult Hodgkin Lymphoma
Stage III Adult Non-Hodgkin Lymphoma
Stage IV Adult Hodgkin Lymphoma
Stage IV Adult Non-Hodgkin Lymphoma

Interventions: Biological: C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs
Drug: Carmustine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine
Drug: Plerixafor

First Posted Date: 2015-01-22

Last Posted Date: 2018-11-20

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02343666

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Colombian Screening Mammography Project

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: Opportunistic Breast cancer screening
Other: Usual Care

First Posted Date: 2015-01-13

Last Posted Date: 2015-01-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15855

Registration Number: NCT02337582

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

Phase 1

Completed

Conditions: Sarcoma

Interventions: Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Other: Laboratory Biomarker Analysis
Radiation: Palliative Radiation Therapy

First Posted Date: 2014-12-18

Last Posted Date: 2017-07-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT02319824

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda

Phase 4

Completed

Conditions: HIV/AIDS and Infections

Interventions: Biological: Hepatitis B vaccine

First Posted Date: 2014-12-12

Last Posted Date: 2019-01-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 132

Registration Number: NCT02316444

Locations: 🇺🇬
Mulago National referral hospital, Kampala, Uganda

Blood Samples to Identify Biomarkers of Busulfan

Active, not recruiting

Conditions: Leukemia
Multiple Myeloma
Immunodeficiency
Myelodysplastic Syndrome
Lymphoma

First Posted Date: 2014-11-17

Last Posted Date: 2024-08-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 139

Registration Number: NCT02291965

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Secondary Myelofibrosis
Primary Myelofibrosis

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Drug: Ruxolitinib
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2014-09-29

Last Posted Date: 2024-03-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 61

Registration Number: NCT02251821

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

Not Applicable

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Device: Health Telemonitoring
Other: Questionnaire Administration
Other: Quality-of-Life Assessment
Procedure: Supportive Care

First Posted Date: 2014-08-27

Last Posted Date: 2020-01-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT02226497

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy